- Home
- INSM vs STLA Comparison
INSM vs STLA Comparison
Compare INSM & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- STLA
- Stock Information
- Founded
- INSM 1988
- STLA 2021
- Country
- INSM United States
- STLA Netherlands
- Employees
- INSM N/A
- STLA N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- STLA Auto Manufacturing
- Sector
- INSM Health Care
- STLA Consumer Discretionary
- Exchange
- INSM Nasdaq
- STLA Nasdaq
- Market Cap
- INSM 29.0B
- STLA 27.0B
- IPO Year
- INSM 2000
- STLA N/A
- Fundamental
- Price
- INSM $162.43
- STLA $10.84
- Analyst Decision
- INSM Strong Buy
- STLA Hold
- Analyst Count
- INSM 19
- STLA 6
- Target Price
- INSM $152.71
- STLA $12.65
- AVG Volume (30 Days)
- INSM 2.2M
- STLA 18.7M
- Earning Date
- INSM 10-30-2025
- STLA 07-29-2025
- Dividend Yield
- INSM N/A
- STLA 5.35%
- EPS Growth
- INSM N/A
- STLA N/A
- EPS
- INSM N/A
- STLA N/A
- Revenue
- INSM $398,105,000.00
- STLA $171,605,402,237.00
- Revenue This Year
- INSM $32.44
- STLA N/A
- Revenue Next Year
- INSM $123.99
- STLA $5.03
- P/E Ratio
- INSM N/A
- STLA N/A
- Revenue Growth
- INSM 21.15
- STLA N/A
- 52 Week Low
- INSM $60.40
- STLA $8.39
- 52 Week High
- INSM $163.22
- STLA $14.28
- Technical
- Relative Strength Index (RSI)
- INSM 80.62
- STLA 67.93
- Support Level
- INSM $156.87
- STLA $10.75
- Resistance Level
- INSM $163.22
- STLA $11.09
- Average True Range (ATR)
- INSM 4.29
- STLA 0.21
- MACD
- INSM 0.73
- STLA 0.15
- Stochastic Oscillator
- INSM 94.51
- STLA 88.28
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.